Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report

Abstract

Objectives Most patients report pain while taking adjuvant endocrine therapy (AET) for the treatment of breast cancer. While studies have examined patients' experiences with side effects, none solely capture patients' experiences with AET‐related pain, a troubling symptom that reduces quality of life and impairs treatment adherence. This study explored themes of AET‐related pain to inform future intervention development. Methods Between November 2017 and November 2018, female patients (n = 30) with early‐stage breast cancer enrolled between 3 and 36 months post‐initiation of AET. Purposeful sampling was stratified by adherence level, age, distress level and time taking AET. Study staff conducted, transcribed and coded semi‐structured interviews via inductive thematic coding to identify pain‐related themes and achieved high inter‐coded reliability (Kappa = 0.96). Results Several pain‐related themes were observed. Attitudes around pain are generally negative, and management needs are largely unmet. Patients reported preferences for non‐pharmacological management strategies and cited AET pain as a reason for medication breaks but not discontinuation. Patients within 19 months of starting AET and low adherers reported more intense and disruptive pain. Conclusions Patients' experiences varied by patient attributes and revealed modifiable factors that may be targeted through behavioural interventions. AET‐related pain is a complex side effect for which psychosocial support may be beneficial.